ClinicalTrials.gg
RecruitingNCT05809310Updated Mar 30, 2025

Effects Branch PA Stenting d-TGA, ToF and TA

An interventional study of Percutaneous intervention (stent) for PA stenosis in Transposition of Great Vessels, Tetralogy of Fallot and Truncus Arteriosus, sponsored by UMC Utrecht. Recruiting at 4 sites in Netherlands. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by UMC Utrecht · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
8 Years and older
Sex
All
01

Study summary

The goal of this randomized controlled trial is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA.

The main question[s] it aims to answer are:

The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions.

Participants will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions.

Researchers will compare the difference in VO2 max (% predicted) between the interventional group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo a percutaneous intervention for a PA stenosis) and the control group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo conservative management)

Read the detailed description

Rationale: Postoperative survival of patients with dextro transposition of the great arteries (d-TGA), Tetralogy of Fallot (ToF) and Truncus Arteriosus (TA) has increased over the last decades due to advances in operative techniques and perioperative care. Despite postoperative survival has increased, morbidity of these patients increases during long-term follow-up with a high need for reinterventions. Right ventricular outflow tract (RVOT) obstructions are the most common indication for a reintervention and percutaneous branch pulmonary artery (PA) interventions account for a significant number of these reinterventions. However, the effects of percutaneous branch PA interventions on exercise capacity, RV function and RV adaptation of patients with d-TGA, ToF and TA remains largely unknown. In addition, there is no consensus about the optimal timing for percutaneous interventions for branch PA stenosis in international guidelines.

Objective: The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions.

Study design: This is a multicenter randomized controlled trial. Patients will be included from the following Dutch interventional centers for congenital heart disease: UMC Utrecht/WKZ (sponsor), LUMC/AUMC and Erasmus MC. During this trial there will be two groups: 1. a group of patients with d-TGA, ToF and TA who will undergo a percutaneous intervention for a branch PA stenosis according to standard care (intervention group) and 2. a group of patients with d-TGA, ToF and TA with a similar degree of pulmonary stenosis as group 1 (class IIa indication) who will undergo conservative management for a branch PA stenosis according to standard care (control group). If necessary, the control group will be able to undergo a percutaneous intervention for branch PA stenosis after the examinations at approximately 6 months follow-up, or sooner in case of symptoms. Patients from both groups will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions.

Study population: d-TGA post ASO, ToF or TA patients ≥8 years old will be included if they have a class IIa indication for a percutaneous intervention for branch PA stenosis according to the international guidelines. Patients will be excluded if they contraindications for one of the examinations.

Main study parameters/endpoints: the difference in VO2 max (% predicted) as parameter for exercise capacity between the interventional and control group.

02

Conditions studied

  • Transposition of Great Vessels
  • Tetralogy of Fallot
  • Truncus Arteriosus
  • Pulmonary Artery Stenosis Supravalvular Congenital
  • Stent Stenosis
  • Right Ventricular Dysfunction
  • Congenital Heart Disease

Keywords

  • Exercise capacity
03

In context

Transposition of Great Vessels

44 studies on the registry are indexed under Transposition of Great Vessels; 9 are open to participants now.

This study's planned enrollment of 56 is close to the median of 56 across 21 interventional studies indexed under Transposition of Great Vessels.

Browse Transposition of Great Vessels studies →

Lead sponsor

UMC Utrecht is the lead sponsor of 364 studies on the registry; 82 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

  • Patients with d-TGA post ASO, ToF or TA
  • ≥8 years

Exclusion criteria

Exclusion Criteria:

One or more of the following inclusion criteria:

  • All class IIa indications for a branch PA intervention:
  • Persistent decreased RV function (based on gold standard CMR)

    • \<18 years RVEF ≤55% (28)
    • ≥18 years RVEF\<50% (29)
  • Progressive tricuspid regurgitation (TR) (≥moderate)
  • Isolated bifurcation stenosis:

    • Significant unilateral stenosis (≥50%)
    • Borderline bilateral PA stenosis (40-70%)
  • Unbalanced perfusion (≤35/65%)
  • RV/LV pressure ratio > 2/3 based on echocardiography
  • Reduced lung perfusion or decreased objective exercise capacity (based of gold standard VO2 max during CPET)

    • \<18 years VO2 peak \<35 mL∙kg-1∙min-1 (boys) VO2 peak \<30 mL∙kg-1∙min-1 (girls) (30)
    • ≥18 years VO2 peak \<27 mL∙kg-1∙min-1 (men) VO2 peak \<19 mL∙kg-1∙min-1 (women) (31)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Interventional group

    Percutaneous intervention for PA stenosis

    Procedure: Percutaneous intervention (stent) for PA stenosis

  • No intervention
    Control group

    Conservative management (percutaneous intervention for PA stenosis 6 months postponed)

Interventions

  • ProcedurePercutaneous intervention (stent) for PA stenosis

    Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries

06

What researchers measure

Primary outcomes

  1. Change from baseline VO2max as percentage of predicted at 6 months as indication of exercise capacity

    using cardiopulmonary exercise test on a treadmill

    Time frame: change between baseline and 6 months follow-up

Secondary outcomes

  1. Technical success using invasive right ventricular and pulmonary artery pressures and gradients

    Technical success of the intervention using invasive right ventricular and pulmonary artery pressures and gradients

    Time frame: after the intervention, an average of 1 month after baseline

  2. Peak workload (W)

    using cardiopulmonary exercise test on a treadmill

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  3. Peak workload (% predicted)

    using cardiopulmonary exercise test on a treadmill

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  4. O2 pulse (ml)

    using cardiopulmonary exercise test on a treadmill

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  5. O2 pulse (% predicted)

    using cardiopulmonary exercise test on a treadmill

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  6. VE/VCO2 slope

    using cardiopulmonary exercise test on a treadmill

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  7. Right ventricular ejection fraction (%)

    using CMR

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  8. RV strain (%)

    using speckle tracking echocardiography and CMR feature tracking

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  9. RV fractional area change (%)

    using echocardiography

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  10. RV pressure (mmHg)

    using echocardiography (TI gradient)

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  11. RV end-systolic elastance

    using pressure-volume analysis

    Time frame: before and after the intervention, an average of 1 month after baseline

  12. RV end systolic volume (ml and ml/m2)

    using CMR

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  13. RV end diastolic volume (ml and ml/m2)

    using CMR

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  14. RV functional reserve

    RVEF dobutamine - RVEF rest using a low dose dobutamine stress MRI

    Time frame: at baseline and 6 months follow-up in the interventional group from UMC Utrecht and Erasmus MC

  15. RV mass (g and g/m2)

    using CMR

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  16. Right ventricular pulmonary arterial (RV-PA) coupling

    using pressure-volume analysis

    Time frame: before and after the intervention, an average of 1 month after baseline

  17. Lung perfusion (%)

    using CMR

    Time frame: at baseline, 6 months follow-up and 2-4 years follow-up

  18. Quality of Life (QoL) in 4 domains: health and related activities, emotional, social and school/work

    using PedsQL questionnaire

    Time frame: at baseline and 2 weeks follow-up

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — We will publish the results in peer-reviewed journals and present them at meetings and conferences. As the data is privacy-sensitive, the database will not be publically available. A request for a collaboration can be made via DataverseNL.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Dec 2027, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2023
First posted
Apr 12, 2023
StartActual
Apr 18, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05809310
Lead sponsor
UMC Utrecht
Collaborators
Dutch Heart Foundation, Hartekind, Erasmus Medical Center, Leiden University Medical Center, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Responsible party
Hans Breur (Dr., UMC Utrecht) — Principal investigator
First posted
Apr 12, 2023
Start date
Apr 18, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 30, 2025

Study contacts

Hans Breur, MD, PhD
Contact
h.breur@umcutrecht.nl
+31 88 75 754 59
Renée Joosen, MSc
Contact
r.s.joosen-2@umcutrecht.nl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion